Hexima Limited [ASX:HXL] share price and news 2022

Company Description

Hexima Limited (HXL) is a biotechnology company actively engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics. Its lead product candidate, HXP124 applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting a 132 patient Australian phase IIb clinical trial of HXP124 for onychomycosis.

Hexima Limited belongs to Health Care sector and under industry of Biotechnology. You can get more information about this company via their website: http://www.hexima.com.au.

This a small cap company with market cap of 17 millions.

Compared to Market and Sector

The following table compares the company to Market and Sector based on Earning, Price/Earning ratio(P/E), Price/Book ratio (P/B) and PE growth.

Company PE is less than both sector and market. while On the other hand, Company Earning is less than both sector and market.

Earnings PE PB PE growth
Company 0 0 2.04 0
Market 0.85 22.3 1.99 0.84
Sector 1.7 39.6 5.78 0.26

Dividend Growth Chart

The following chart shows you how hxl dividend grows in the recent years.

No data